The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes
Open accessAbstract
BACKGROUND: We investigated whether intensive glycemic control, combination therapy for dyslipidemia, and intensive blood-pressure control would limit the progression of diabetic retinopathy in persons with type 2 diabetes. Previous data suggest that these systemic factors may be important in the development and progression of diabetic retinopathy. METHODS: In a randomized trial, we enrolled 10,251 participants with type 2 diabetes who were at high risk for cardiovascular disease to receive either intensive or standard treatment for glycemia (target glycated hemoglobin level, <6.0% or 7.0 to 7.9%, respectively) and also for dyslipidemia (160 mg daily of fenofibrate plus simvastatin or placebo plus simvastatin) or for systolic blood-pressure control (target, <120 or <140 mm Hg). A subgroup of 2856 participants was evaluated for the effects of these interventions at 4 years on the progression of diabetic retinopathy by 3 or more steps on the Early Treatment Diabetic Retinopathy Study Severity Scale (as assessed from seven-field stereoscopic fundus photographs, with 17 possible steps and a higher number of steps indicating greater severity) or the development of diabetic retinopathy necessitating laser photocoagulation or vitrectomy. RESULTS: At 4 years, the rates of progression of diabetic retinopathy were 7.3% with intensive glycemia treatment, versus 10.4% with standard therapy (adjusted odds ratio, 0.67; 95% confidence interval [CI], 0.51 to 0.87; P=0.003); 6.5% with fenofibrate for intensive dyslipidemia therapy, versus 10.2% with placebo (adjusted odds ratio, 0.60; 95% CI, 0.42 to 0.87; P=0.006); and 10.4% with intensive blood-pressure therapy, versus 8.8% with standard therapy (adjusted odds ratio, 1.23; 95% CI, 0.84 to 1.79; P=0.29). CONCLUSIONS: Intensive glycemic control and intensive combination treatment of dyslipidemia, but not intensive blood-pressure control, reduced the rate of progression of diabetic retinopathy. (Funded by the National Heart, Lung, and Blood Institute and others; ClinicalTrials.gov numbers, NCT00000620 for the ACCORD study and NCT00542178 for the ACCORD Eye study.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary composite major CV outcomes (nonfatal MI, nonfatal stroke or death from CV causes) were not reduced significantly in ACCORD (hazard ratio [HR] 0.90, p=0.16).”
From Targets for Glycemic Control (2018) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with type 2 diabetes, an A1C ≤6.5% may be targeted to reduce the risk of CKD [Grade A, Level 1A (23)] and retinopathy [Grade A, Level 1A (21)], if they are assessed to be at low risk of hypoglycemia based on class of antihyperglycemic medication(s) utilized and the person's characteristics [Grade D, Consensus].”
From Targets for Glycemic Control (2018) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The UK Prospective Diabetes Study randomly assigned 4209 patients with newly diagnosed type 2 diabetes to receive conventional (primarily diet) vs intensive (insulin, sulfonylurea, or, if overweight, metformin) treatment, with mean attained HbA1C of 7.9% vs 7.0%, respectively.36,37”
From Diagnosis and Treatment of Type 2 Diabetes in Adults (2025) · cites this paper as [36]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Other options that can stabilize retinopathy include lifestyle intervention or bariatric surgery in persons with T2D or physical activity in persons with T1D.524–527”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [527]
Experimental — accuracy not yet measuredIn the citing paper
“Fenofibrate reduces the progression of diabetic retinopathy.413,414”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [414]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Self-citationIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Self-citationStearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 4,803
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,023
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Self-citation
Flagged first, then by citations
Research works printed but not linked: 4
- Davis MD, 1998, Invest Ophthalmol Vis Sci, 39, 233
- Cullen JF, 1964, Trans Ophthalmol Soc U K, 84, 281
- The ACCORD Study Group, 2007, Am J Cardiol, 99, 21i
- Ismail-Beigi F, 2010, Lancet, 375, 26
Cited by
Sorted by citations
Items 501–600 of 1,000
Non-Traditional Systemic Treatments for Diabetic Retinopathy: An Evidence-Based Review
Simó, R., Ballarini, S., Cunha-Vaz, J. G., Ji, L., Haller, H. G., Zimmet, P., & Wong, T. Y. (2015) · Current Medicinal Chemistry · doi:10.2174/0929867322666150520095923 · Cited by 26
Prevention of complications in type 2 diabetes: is drug glucose control evidence based?
Boussageon, R., Pouchain, D., & Renard, V. (2017) · British Journal of General Practice · doi:10.3399/bjgp17x689317 · Cited by 28
Insulin Resistance and a Long, Strange Trip
Semenkovich, C. F. (2016) · New England Journal of Medicine · doi:10.1056/nejme1600962 · Cited by 26
Yuan, T., Dong, L., Pearsall, E., Zhou, K., Cheng, R., & Ma, J. (2022) · Cells · doi:10.3390/cells11233869 · Cited by 25
Genetic Studies on Diabetic Microvascular Complications: Focusing on Genome-Wide Association Studies
Kwak, S. H., & Park, K. S. (2015) · Endocrinology and Metabolism · doi:10.3803/enm.2015.30.2.147 · Cited by 25
The relationship between carotid disease and retinopathy in diabetes: a systematic review
Drinkwater, J. J., Davis, T. M. E., & Davis, W. A. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01023-6 · Cited by 25
Park, J., Hwang, J. H., Kang, M. J., Sim, H. E., Kim, J. S., & Ko, K. S. (2020) · Retina · doi:10.1097/iae.0000000000003049 · Cited by 27
Metabolism in Retinopathy of Prematurity
Tomita, Y., Usui‐Ouchi, A., Nilsson, A., Yang, J., Ko, M., Hellström, A., & Fu, Z. (2021) · Life · doi:10.3390/life11111119 · Cited by 25
Jang, H. N., Moon, M. K., & Koo, B. K. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0099 · Cited by 28
Hammer, S. S., Dorweiler, T. F., McFarland, D., Adu-Agyeiwaah, Y., Mast, N., El‐Darzi, N., Fortmann, S. D., Nooti, S. K., Agrawal, D. K., Pikuleva, I. A., et al. (2023) · Diabetologia · doi:10.1007/s00125-023-05949-w · Cited by 24
Towler, D. A. (2013) · Journal of Clinical Investigation · doi:10.1172/jci72326 · Cited by 25
Feng, J., Chu, L. M., Dobrilovic, N., Liu, Y., Singh, A. K., & Sellke, F. W. (2012) · Surgery · doi:10.1016/j.surg.2012.04.009 · Cited by 25
Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia
Filippatos, T. D., & Elisaf, M. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.593509 · Cited by 25
Santos‐Bezerra, D. P., Santos, A. S., Guimarães, G. C., Admoni, S. N., Perez, R. V., Machado, C. G., Pelaes, T. S., Passarelli, M., Machado, U. F., Queiroz, M. S., et al. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00385 · Cited by 25
Shi, L., Ye, X., Lü, M., Wu, E. Q., Sharma, H., Thomason, D., & Fonseca, V. A. (2013) · Diabetes Care · doi:10.2337/dc13-0149 · Cited by 25
Hanaguri, J., Nagai, N., Yokota, H., Kushiyama, A., Watanabe, M., Yamagami, S., & Nagaoka, T. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020384 · Cited by 24
Kim, N. H., Choi, J., Kim, Y. H., Lee, H., & Kim, S. G. (2023) · Diabetes & Metabolism · doi:10.1016/j.diabet.2023.101428 · Cited by 25
Glucose control in diabetes: which target level to aim for?
Laakso, M., & Cederberg, H. (2012) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2012.02528.x · Cited by 25
Association of retinal microvascular caliber with blood pressure levels
Gepstein, R., Rosman, Y., Rechtman, E., Koren‐Morag, N., Segev, S., Assia, E. I., & Grossman, E. (2012) · Blood Pressure · doi:10.3109/08037051.2012.645336 · Cited by 24
Molecular Implications of the PPARs in the Diabetic Eye
Ciudin, A., Hernández, C., & Simó, R. (2013) · PPAR Research · doi:10.1155/2013/686525 · Cited by 24
Caveats to aggressive lowering of lipids by specific statins
Koh, K. K., Lim, S. K., Sakuma, I., & Quon, M. J. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.09.002 · Cited by 24
Fenofibrate in cancer: mechanisms involved in anticancer activity
Koltai, T. (2015) · F1000Research · doi:10.12688/f1000research.6153.1 · Cited by 24
Sharma, N., Ooi, J., Ong, J., & Newman, D. (2015) · PubMed · Cited by 24
Campbell, M. D., Laitinen, T. T., Hughes, A. D., Pahkala, K., Juonala, M., Kähönen, M. A. P., Wong, T. Y., Lehtimäki, T. J., Hutri‐Kähönen, N., Raitakari, O. T., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009487 · Cited by 24
Tillin, T., Orchard, T. J., Malm, A. R., Fuller, J., & Chaturvedi, N. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283480db9 · Cited by 23
Lammer, J., Bolz, M., Baumann, B., Pircher, M., Götzinger, E., Mylonas, G., Hitzenberger, C. K. F., & Schmidt-Erfurth, U. M. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2012.12.017 · Cited by 23
What are the pharmacotherapy options for treating prediabetes?
Daniele, G., Abdul‐Ghani, M. A., & DeFronzo, R. A. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.944160 · Cited by 23
Recent Advancements in the Medical Treatment of Diabetic Retinal Disease
Szymanska, M., Mahmood, D., Yap, T. E., & Cordeiro, M. F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179441 · Cited by 23
Lee, D., Tomita, Y., Jeong, H., Miwa, Y., Tsubota, K., Negishi, K., & Kurihara, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179408 · Cited by 24
Reverse Cholesterol Transport Pathway and Cholesterol Efflux in Diabetic Retinopathy
Zhang, X., Wang, K., Zhu, L., & Wang, Q. (2021) · Journal of Diabetes Research · doi:10.1155/2021/8746114 · Cited by 23
Yang, S., Zhu, Z., Chen, S., Yuan, Y., He, M., & Wang, W. (2023) · Nature Communications · doi:10.1038/s41467-023-42404-1 · Cited by 23
Review of therapeutic advances in diabetic retinopathy
Chen, C. G., & Shah, C. P. (2011) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018810396750 · Cited by 23
Feng, J., Liu, Y., Dobrilovic, N., Chu, L. M., Bianchi, C. F., Singh, A. K., & Sellke, F. W. (2013) · Circulation · doi:10.1161/circulationaha.112.000332 · Cited by 23
Relationships among Diabetic Retinopathy, Antioxidants, and Glycemic Control
Lam, C. S. Y., Benzie, I. F. F., Choi, S. W., Chan, L. Y. L., Yeung, V., & Woo, G. C. (2011) · Optometry and Vision Science · doi:10.1097/opx.0b013e318208494a · Cited by 23
Serum fibroblast growth factor 21 concentrations in type 2 diabetic retinopathy patients
Esteghamati, A., Momeni, A., Abdollahi, A. A., Khandan, A., Afarideh, M., Noshad, S., & Nakhjavani, M. (2016) · Annales d Endocrinologie · doi:10.1016/j.ando.2016.01.005 · Cited by 23
Role of lipid-lowering agents in the management of diabetic retinopathy
Ioannidou, E., Tseriotis, V., & Τζιόμαλος, Κ. (2017) · World Journal of Diabetes · doi:10.4239/wjd.v8.i1.1 · Cited by 24
Sato, S., Shinoda, H., Nagai, N., Suzuki, M., Uchida, A., Kurihara, T., Kamoshita, M., Tomita, Y., Iyama, C., Minami, S., et al. (2017) · Medicine · doi:10.1097/md.0000000000006459 · Cited by 23
Usui‐Ouchi, A., Ouchi, Y., & Ebihara, N. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.08.027 · Cited by 23
Liu, Y., Li, J., Ma, J., & Tong, N. (2020) · Journal of Diabetes Research · doi:10.1155/2020/8765139 · Cited by 25
Systemic medical management of diabetic retinopathy
Gopal, L., & Wong, T. Y. (2013) · Middle East African Journal of Ophthalmology · doi:10.4103/0974-9233.120010 · Cited by 23
Safety considerations with fenofibrate/simvastatin combination
Filippatos, T. D., & Elisaf, M. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1056778 · Cited by 22
Jacoba, C. M. P., Celi, L. A., & Silva, P. S. (2021) · Seminars in Ophthalmology · doi:10.1080/08820538.2021.1893351 · Cited by 24
Hyperglycemia Promotes Mitophagy and Thereby Mitigates Hyperglycemia-Induced Damage
Serikbaeva, A., Li, Y., Ganesh, B. B., Zelkha, R., & Kazlauskas, A. (2022) · American Journal Of Pathology · doi:10.1016/j.ajpath.2022.08.004 · Cited by 22
Blot, G., Karadayi, R., Przegralek, L., Sartoris, T.-M., Charles‐Messance, H., Augustin, S., Négrier, P., Blond, F., Muñiz-Ruvalcaba, F. P., la Parra, D. R.-D., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci161348 · Cited by 22
Overcoming Obstacles in Risk Factor Management in Type 2 Diabetes Mellitus
Handelsman, Y., & Jellinger, P. S. (2011) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2011.00490.x · Cited by 22
Management of diabetic retinopathy.
Ellis, D., Burgess, P. I., & Kayange, P. (2013) · Europe PMC (PubMed Central) · Cited by 24
Tyrberg, M., Nyström, L., Arnqvist, H. J., Bolinder, J., Guðbjörnsdóttir, S., Landin‐Olsson, M., Eriksson, J. W., & Svensson, M. K. E. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.08.009 · Cited by 24
Gower, E. W., Lovato, J. F., Ambrosius, W. T., Chew, E. Y., Danis, R. P., Davis, M. D., Goff, D. C., Greven, C. M., Gotto, A. M., Bailey, K. R., et al. (2017) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2017.12.007 · Cited by 22
Lee, M., Hsiao, P., Huang, J., Hsu, W., Chen, S., Chang, J., & Shin, S. (2018) · Endocrine Practice · doi:10.4158/ep-2017-0254 · Cited by 24
Optimal treatment of diabetic retinopathy
Hammes, H. (2013) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018813477886 · Cited by 24
Thyroid dysfunction in patients with diabetic retinopathy
Stefanowicz-Rutkowska, M. M., Baranowska-Jurkun, A., Matuszewski, W., & Bandurska-Stankiewicz, E. M. (2020) · Endokrynologia Polska · doi:10.5603/ep.a2020.0013 · Cited by 21
Ang, I. Y. H., Tan, X. Q., Tan, C. M., Tan, C. H., Kwek, J. W. M., Tay, J., & Toh, S.-A. E. S. (2021) · JMIR Diabetes · doi:10.2196/25820 · Cited by 20
Preiss, D., Spata, E., Holman, R. R., Coleman, R. L., Lovato, L., Ginsberg, H. N., & Armitage, J. (2021) · Diabetes Care · doi:10.2337/dc21-1439 · Cited by 21
Screening and Treatment by the Primary Care Provider of Common Diabetes Complications
Gilbert, M. P. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.09.002 · Cited by 22
Fenofibrate Ameliorates Oxidative Stress-Induced Retinal Microvascular Dysfunction in Diabetic Rats
Li, J., Wang, P., Chen, Z., Yu, S., & Xu, H. (2018) · Current Eye Research · doi:10.1080/02713683.2018.1501072 · Cited by 22
Fenofibrate and Dyslipidemia: Still a Place in Therapy?
Tarantino, N. M., Santoro, F., Correale, M., Gennaro, L. D., Romano, S., Biase, M. D., & Brunetti, N. D. (2018) · Drugs · doi:10.1007/s40265-018-0965-8 · Cited by 21
Chen, Z., & Li, G. (2019) · Clinical Drug Investigation · doi:10.1007/s40261-019-00781-w · Cited by 23
Couturier, A., Blot, G., Vignaud, L., Nanteau, C., Slembrouck-Brec, A., Fradot, V., Acar, N., Sahel, J., Tadayoni, R., Thuret, G., et al. (2021) · Glia · doi:10.1002/glia.23983 · Cited by 21
Chapter 4: Blood pressure management in CKD ND patients with diabetes mellitus
(2012) · Kidney International Supplements · doi:10.1038/kisup.2012.54 · Cited by 21
Abcouwer, S. F. (2012) · Diabetes · doi:10.2337/db12-1223 · Cited by 23
Update of the ACCORD Eye Study
Chew, E. Y., & Ambrosius, W. T. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1011499 · Cited by 21
Mellor, J., Jeyam, A., Beulens, J. W. J., Bhandari, S., Broadhead, G., Chew, E. Y., Fickweiler, W., van der Heijden, A. A. W. A., Gordin, D., Simó, R., et al. (2024) · Ophthalmology Science · doi:10.1016/j.xops.2024.100494 · Cited by 23
Torres-Cuevas, I., Millán, I., Asensi, M. A., Vento, M., Oger, C., Galano, J., Durand, T., & Ortega, Á. (2021) · Antioxidants · doi:10.3390/antiox10020168 · Cited by 21
González‐González, J. G., Solís, R. C., González-Colmenero, A. D., Raygoza-Cortez, K., Moreno-Peña, P. J., Sánchez, A. L., McCoy, R. G., Ospina, N. S., Maraka, S., Brito, J. P., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109821 · Cited by 22
Dietary Risk Factors and Eating Behaviors in Peripheral Arterial Disease (PAD)
Cecchini, A. L., Biscetti, F., Rando, M. M., Nardella, E., Pecorini, G., Eraso, L. H., DiMuzio, P. J., Gasbarrini, A., Massetti, M., & Flex, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810814 · Cited by 28
Fuior, E. V., Zvintzou, E., Filippatos, T. D., Giannatou, K., Mparnia, V., Simionescu, M., Gafencu, A. V., & Kypreos, K. E. (2023) · Biomedicines · doi:10.3390/biomedicines11102696 · Cited by 25
Diabetic Retinopathy—Update on Prevention Techniques, Present Therapies, and New Leads
Marozas, L. M., Fort, P. E., & Student, U. (2014) · touchREVIEWS in Ophthalmology · doi:10.17925/usor.2014.07.01.54 · Cited by 22
Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians
Hermans, M. P., & Fruchart, J. (2011) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622311413952 · Cited by 20
Do Persons with Diabetes Benefit from Combination Statin and Fibrate Therapy?
Rosenblit, P. D. (2012) · Current Cardiology Reports · doi:10.1007/s11886-011-0237-7 · Cited by 20
Medical management of diabetic retinopathy: an overview.
Malek, M., Khamseh, M. E., Aghili, R., Emami, Z., Najafi, L., & Baradaran, H. R. (2012) · PubMed · Cited by 20
Porojan, M. D., Catana, A. M., Popp, R. A., Dumitrascu, D. L., & Bala, C. G. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s93172 · Cited by 20
Arteriole Tortuosity Associated with Diabetic Retinopathy and Cholesterol
Weiler, D. L., Engelke, C. B., Moore, A. L., & Harrison, W. W. (2014) · Optometry and Vision Science · doi:10.1097/opx.0000000000000484 · Cited by 20
Fujita, N., Sase, K., Tsukahara, C., Arizono, I., Takagi, H., & Kitaoka, Y. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-06032-y · Cited by 20
Impact of fenofibrate therapy on serum uric acid concentrations: a review and meta-analysis
Zhang, J., Ji, X., Dong, Z., Lü, J., Zhao, Y., Li, R., Li, C., & Chen, Y. (2021) · Endocrine Journal · doi:10.1507/endocrj.ej20-0808 · Cited by 20
Management of proliferative diabetic retinopathy
Hendrick, A. M., & Ip, M. S. (2015) · Springer eBooks · doi:10.1007/978-3-319-08329-2_9 · Cited by 20
Lee, S., Cho, K. I., Kim, J., Ahn, Y. K., Rha, S., Kim, Y.-J., Choi, Y. S., Choi, S. W., Jeon, D. W., Min, P., et al. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.12.042 · Cited by 20
Caring for visually impaired patients
Orrico, K. B. (2013) · Journal of the American Pharmacists Association · doi:10.1331/japha.2013.13514 · Cited by 20
Sobrin, L., Chong, Y. H., Fan, Q., Gan, A. T. L., Stanwyck, L. K., Kaidonis, G., Craig, J. E., Kim, J., Liao, W., Huang, Y., et al. (2017) · Diabetes · doi:10.2337/db17-0398 · Cited by 20
Peng, L., Sun, B., Liu, M., Huang, J., Liu, Y., Xie, Z., He, J., Chen, L., Wang, D. W., Zhu, Y., et al. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.01.188 · Cited by 19
Mashele, T. S., Mogale, M. A., Towobola, O. A. P., & Moshesh, M. F. (2018) · South African Family Practice · doi:10.1080/20786190.2018.1527134 · Cited by 19
Improving the screening of risk factors in diabetic retinopathy
Scanlon, P. H. (2022) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2022.2078305 · Cited by 24
Chen, H.-S., Wu, T., Hsiao, L., & Lin, S. (2011) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2011.02616.x · Cited by 19
Rosenson, R. S., Carlson, D. M., Kelly, M. T., Setze, C. M., Hirshberg, B., Stolzenbach, J. C., & Williams, L. A. (2010) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-010-6273-5 · Cited by 19
Aranda, J., Motiejūnaitė, R., Im, E., & Kazlauskas, A. (2012) · Diabetes · doi:10.2337/db11-1189 · Cited by 19
Azad, N., Bahn, G., Emanuele, N., Agrawal, L., Ge, L., Reda, D. J., Klein, R., Reaven, P. D., Hayward, R. A., & the VADT Study Group (2016) · Diabetes Care · doi:10.2337/dc15-1897 · Cited by 19
Self-citationSemenkovich, C. F. (2017) · Diabetes · doi:10.2337/db17-0093 · Cited by 19
Corbi, S. C. T., Bastos, A. D. S., Nepomuceno, R., Cirelli, T., dos Santos, R. A., Takahashi, C. S., Rocha, C. S., Orrico, S. R. P., Maurer‐Morelli, C. V., & Scarel‐Caminaga, R. M. (2017) · Journal of Diabetes Research · doi:10.1155/2017/2180819 · Cited by 19
Gerstein, H. C., Smith, E. E., Ramasundarahettige, C. F., Desai, D., Awadalla, P., Broët, P., Black, S. E., Dummer, T., Hicks, J., Moody, A. R., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa815 · Cited by 19
Kang, E. Y., Kang, C., Wu, W., Sun, C., Chen, K., Lai, C., Chen, T., & Hwang, Y. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132871 · Cited by 20
Zhu, C., Zhang, S.-S., Kong, Y., Bi, Y., Wang, L., & Zhang, Q. (2013) · Europe PMC (PubMed Central) · doi:10.3980/j.issn.2222-3959.2013.02.06 · Cited by 19
Diabetes and cardiovascular disease in older adults
Bilal, A., & Pratley, R. E. (2024) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15259 · Cited by 18
Ng, D. S., Ruamviboonsuk, P., Apte, R. S., Bajimaya, S., Chan, C. K. M., Chang, A., Cheung, C. Y.-L., Chen, S. J., Chaudhary, V., Chaikitmongkol, V., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101406 · Cited by 18
Is Fenofibrate a Reasonable Treatment for Diabetic Microvascular Disease?
Simó, R., Simó‐Servat, O., & Hernández, C. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0599-0 · Cited by 18
Individualizing treatment targets in diabetes care
Buse, J. B. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.230 · Cited by 18
Chiu, T.-T., Tsai, T.-L., Su, M.-Y., Yang, T., Tseng, P.-L., Lee, Y., & Lee, C.-H. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18010307 · Cited by 18
Diabetes mellitus associated neurovascular lesions in the retina and brain: A review
Sinclair, S. H., Miller, E. S., Talekar, K. S., & Schwartz, S. S. (2022) · Frontiers in Ophthalmology · doi:10.3389/fopht.2022.1012804 · Cited by 18
Effects of systemic drugs on the development and progression of age-related macular degeneration
Grimes, K. R., Aloney, A., Skondra, D., & Chhablani, J. (2023) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2023.01.007 · Cited by 22
Genome-Wide Associations and Confirmatory Meta-Analyses in Diabetic Retinopathy
Yu, X.-T., & Rong, S.-S. (2023) · Genes · doi:10.3390/genes14030653 · Cited by 16
Advances in the treatment of diabetic retinopathy
El‐Asrar, A. M. A., & Al‐Mezaine, H. S. (2011) · Saudi Journal of Ophthalmology · doi:10.1016/j.sjopt.2011.01.005 · Cited by 18
Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?
Zannad, F. M., Stough, W. G., Pocock, S., Sleight, P., Cushman, W. C., Cleland, J. G. F., McMurray, J. J. V., Lonn, E., Geller, N. L., Wedel, H., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehr437 · Cited by 18
Metadata
- Authors
- The ACCORD Study Group and ACCORD Eye Study Group
- Corresponding author
- The ACCORD Study Group and ACCORD Eye Study Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-07-15
- Volume
- 363
- Issue
- 3
- Pages
- 233-244
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4026164
- OpenAlex
- W2219384223
- Semantic Scholar
- 9a607a3bfd9432a917f703d573fdaa1052647711
- Cited by
- 1,311
- References
- 36
- Citations by year
- 2026: 54 · 2025: 60 · 2024: 66 · 2023: 86 · 2022: 73 · 2021: 94 · 2020: 96 · 2019: 57 · 2018: 78 · 2017: 87 · 2016: 82 · 2015: 84 · 2014: 74 · 2013: 81 · 2012: 93
- FWCI
- 111.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Abbott Laboratories
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Regeneron Pharmaceuticals
- Massachusetts Medical Society
- Omron Healthcare
- Bayer HealthCare
- Daiichi-Sankyo
- Novo Nordisk
- Servier
- National Institutes of Health (n01hc95183-23-0-0, n01hc95180-24-0-1, n01hc95184-24-0-1, n01hc95181-23-0-1, n01hc95182-23-0-1, Z99 EY999999, n01hc95178-28-0-1, n01hc95179-25-0-0)
- Centers for Disease Control and Prevention
- National Institute on Aging
- National Heart, Lung, and Blood Institute (N01- HC-95181, R01HL073030, N01 HC095184, N01-HC- 95180, N01-HC-95178, N01 HC095182, N01 HC095181, Y01 HC001010, N01-HC-095183, N01 HC095178, N01-HC-95184, N01HC95179, IAAY1-HC-1010, IAA #Y1-HC-9035, N01 HC095180, Y01 HC009035, N01‐HC‐95183, N01-HC-95182, N01 HC095179)
- National Eye Institute (ZIAEY000410)
- National Institute of Diabetes and Digestive and Kidney Diseases
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- diabetic retinopathy, retinopathy progression, type 2 diabetes, tight glycemic control, HbA1c, fenofibrate, simvastatin, dyslipidemia, blood pressure control, laser photocoagulation, vitrectomy, cardiovascular risk reduction, combination therapy, Early Treatment Diabetic Retinopathy Study
- MeSH terms
- Antihypertensive Agents, Hypolipidemic Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Retinopathy, Drug Therapy, Combination, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hyperglycemia, Hypertension, Hypoglycemic Agents, Cholesterol, LDL, Male, Middle Aged, Fenofibrate, Disease Progression, Simvastatin, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
